A recent study comparing BRCA1/2 variant status between germline and somatic testing results showed 100 percent concordance, providing validation for the use of tumour testing to the determine potential utility of treatment, as well as hereditary cancer risk [19]. This evidence concerns the gene BRCA1 and neoplasm.